![](/img/cover-not-exists.png)
P-976 EGFR mutation analysis in a randomized phase II study of cetuximab (Erbitux™) in combination with cisplatin (C) and vinorelbine (V) vs CV alone in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) patients (pts)
Szczesna, A., Taron, M., Robinet, G., Ramlau, R., Pfeifer, W., Kolb, R., Constenla, M., Pirker, R., Gascon, N., Gatzemeier, U.Volume:
49
Language:
english
Journal:
Lung Cancer
DOI:
10.1016/S0169-5002(05)81469-2
Date:
July, 2005
File:
PDF, 117 KB
english, 2005